Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
38
SXTC Quote, Financials, Valuation and Earnings
Last price:
$1.37
Seasonality move
:
24.22%
Day range:
$1.35 - $1.43
52-week range:
$0.95 - $7.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.62x
P/B ratio:
48.72x
Volume:
36.3K
Avg. volume:
221.8K
1-year change:
-53.38%
Market cap:
$160.1M
Revenue:
$1.7M
EPS (TTM):
-$16.37
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, China Sxt Pharmaceuticals, Inc. has -- downside to fair value with a price target of -- per share.
SXTC vs. S&P 500
-
Over the past 5 trading days, China Sxt Pharmaceuticals, Inc. has underperformed the S&P 500 by -2.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
China Sxt Pharmaceuticals, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
China Sxt Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter China Sxt Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
China Sxt Pharmaceuticals, Inc. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter China Sxt Pharmaceuticals, Inc. reported earnings per share of --.
Enterprise value:
159.8M
EV / Invested capital:
--
Price / LTM sales:
5.62x
EV / EBIT:
3.83x
EV / Revenue:
91.82x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-68.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
3.73x
Gross Profit (TTM):
$554K
Return On Assets:
-13.82%
Net Income Margin (TTM):
-160.67%
Return On Equity:
-27.59%
Return On Invested Capital:
-21.9%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-03-31 | 2017-03-31 | 2018-03-31 | 2017-03-31 | 2018-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $7M | -- | $1.4M | |
| Gross Profit | -- | -- | -- | -- | $812K | |
| Operating Income | -- | -- | $1.6M | -- | $300.1K | |
| EBITDA | -- | -- | $1.6M | -- | $329.8K | |
| Diluted EPS | -- | -- | -- | -- | $120.64 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $23.2M | $22.5M | $19.5M | $14.2M | $21.3M | |
| Total Assets | $34.5M | $33.5M | $29.6M | $23.1M | $21.7M | |
| Current Liabilities | $18.6M | $17.1M | $14.5M | $8.9M | $6M | |
| Total Liabilities | $18.6M | $17.1M | $14.9M | $9.2M | $6.2M | |
| Total Equity | $16M | $16.4M | $14.7M | $13.9M | $15.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-09 | 2024-12-09 | 2024-12-09 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
SXTC
Sector
Market Cap
$160.1M
$28.5M
Price % of 52-Week High
17.6%
51.43%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.33%
1-Year Price Total Return
-53.38%
-21.18%
Beta (5-Year)
1.447
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.41
200-day SMA
Sell
Level
$1.93
Bollinger Bands (100)
Sell
Level
1.37 - 1.69
Chaikin Money Flow
Buy
Level
21.9M
20-day SMA
Sell
Level
$1.39
Relative Strength Index (RSI14)
Sell
Level
47.73
ADX Line
Buy
Level
25.25
Williams %R
Neutral
Level
-77.1429
50-day SMA
Sell
Level
$1.43
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
274.9M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.1718)
Buy
CA Score
(Annual)
Level (-0.0574)
Buy
Beneish M-Score
(Annual)
Level (-2.7776)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.213)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.
Stock Forecast FAQ
In the current month, SXTC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SXTC average analyst price target in the past 3 months is --.
-
Where Will China Sxt Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that China Sxt Pharmaceuticals, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About China Sxt Pharmaceuticals, Inc.?
Analysts are divided on their view about China Sxt Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that China Sxt Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is China Sxt Pharmaceuticals, Inc.'s Price Target?
The price target for China Sxt Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SXTC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for China Sxt Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SXTC?
You can purchase shares of China Sxt Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase China Sxt Pharmaceuticals, Inc. shares.
-
What Is The China Sxt Pharmaceuticals, Inc. Share Price Today?
China Sxt Pharmaceuticals, Inc. was last trading at $1.37 per share. This represents the most recent stock quote for China Sxt Pharmaceuticals, Inc.. Yesterday, China Sxt Pharmaceuticals, Inc. closed at $1.38 per share.
-
How To Buy China Sxt Pharmaceuticals, Inc. Stock Online?
In order to purchase China Sxt Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SXTC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SXTC
Sector
P/E ratio
--
23.66x
PEG ratio
-0.01x
-0.01x
P/B ratio
48.72x
1.82x
Price / LTM sales
5.62x
1.61x
Growth Metrics
SXTC
Sector
Revenue growth
--
4.8%
Earnings growth
--
11.11%
Revenue (5-year growth)
-19.54%
6.45%
Earnings forecast
--
-$0.20
Profitability
SXTC
Sector
Profitability FY 2024
$367.4K
$3.6M
Return on invested capital
-21.9%
-31.15%
Return on assets
-13.82%
-27.72%
Return on equity
-27.59%
-36.72%
Earnings Date
Last Earnings Date
Dec
9
Next Earnings Date
Dec
9
Estimated Next Earnings Date
Mar
10
Balance Sheet
SXTC
Sector
Total cash
$12.1M
$27M
Short term investments
--
$25.7M
Total assets
$21.7M
$79.7M
Long term debt
$2.4M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is down 2.44% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 3.73% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is down 7.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
